The demographic and baseline characteristics, including age, sex, BMI, diabetes duration, FBG, HbA1c, serum creatinine, SBP, DBP, urine ratio of albumin/creatinine, incidence of hypertension, incidence of microvascular complications, and application of GLDs background, in the treatment group were comparable to 39 patients who were treated with their routine GLDs (p > 0.05) in the control group. This evidence concerns the gene ALB and hypertensive disorder.